Exploring Three High Growth Tech Stocks In The United States
Over the last 7 days, the United States market has remained flat, yet it is up 30% over the past year with earnings forecasted to grow by 15% annually. In this context of robust growth potential, ...
RBC Capital Sticks to Their Hold Rating for Gilead Sciences (GILD)
In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price ...
Piper Sandler Reaffirms Their Buy Rating on CARGO Therapeutics, Inc. (CRGX)
In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on CARGO Therapeutics, Inc. (CRGX – Research Report), with a ...
Los Angeles Business Journal2d
Arrowhead Pharma Shares See Big Price Jump
The share price in Arrowhead Pharmaceuticals Inc. jumped by more than 48% in the two months since it hit its lowest value of the past year. On Oct. 10, ...
Why Is Sarepta Therapeutics (SRPT) Up 4.9% Since Last Earnings Report?
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Muscular Dystrophy News6d
Arrakis’ RNA-targeted oral therapies showing promise for DM1
Arrakis' oral therapies targeting disease-driving RNA in myotonic dystrophy have shown promise in preclinical studies.
Quantbot Technologies LP Buys New Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Quantbot Technologies LP bought a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) during the 3rd quarter, according to its most recent filing with the Securities and ...